Please login to the form below

Not currently logged in
Email:
Password:

AbbVie’s uterine fibroids drug aces second phase III trial

An FDA verdict is expected in the US in the coming weeks

Abbott headquarters

AbbVie and Neurocrine Biosciences have a second positive phase III trial in hand for their uterine fibroids drug elagolix - setting up another regulatory filing for the drug.

The two companies are currently waiting for an FDA verdict in the US in the coming weeks on elagolix as a treatment for endometriosis-related pain, but uterine fibroids are another big market opportunity that could help fulfil AbbVie’s blockbuster expectations for the orally-active gonadotropin-releasing hormone (GnRH) receptor antagonist.

Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the age of 50. In many cases they cause no symptoms, but around a quarter of women experience pain, abnormal bleeding and other symptoms, with some finding they have difficulty getting pregnant. African American women are more likely to experience fibroids and tend to develop them at a younger age.

The results of the EULARIS UF-II trial mirror data from the ELARIS UF-I study reported last month and showed that treatment with elagolix in combination with low-dose hormonal therapy reduced heavy menstrual bleeding in 76% of women, compared to just 10% of the comparative placebo arm. A response was defined as menstrual blood loss volume of less than 80ml during the sixth month and a 50% or greater reduction from baseline to month six.

“Millions of women currently diagnosed with uterine fibroids are faced with limited non-surgical options," commented Dawn Carlson, AbbVie’s vice president of general medicine development. "The results from this study demonstrate elagolix has the potential to be an important oral treatment option for women suffering from uterine fibroids.”

Analysts at Piper Jaffray said after the first trial was announced that the efficacy data looks good and that 12-month data from both trials should be ready later this year or in early 2019, setting up a possible launch in uterine fibroids in 2020. Meanwhile, multiple analysts previously predicted $1bn-plus in sales for elagolix in endometriosis alone, with uterine fibroids giving additional upside potential. AbbVie in-licensed the drug from Neurocrine in 2010 for $575 million.

Elagolix isn’t the only drug aiming to provide an oral therapy for uterine fibroids. Last year, Takeda and Myovant reported positive mid-stage results with their relugolix candidate in this indication as well as endometriosis-related pain and prostate cancer.

Myovant has rights to the drug outside certain Asian markets and has a phase III programme ongoing due to read out in 2019.

Article by
Phil Taylor

14th March 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics